WO2001060412A3 - Modification of biopolymers for improved drug delivery - Google Patents
Modification of biopolymers for improved drug delivery Download PDFInfo
- Publication number
- WO2001060412A3 WO2001060412A3 PCT/US2001/004925 US0104925W WO0160412A3 WO 2001060412 A3 WO2001060412 A3 WO 2001060412A3 US 0104925 W US0104925 W US 0104925W WO 0160412 A3 WO0160412 A3 WO 0160412A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biopolymers
- modification
- drug delivery
- improved drug
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001238346A AU2001238346A1 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
IL15102401A IL151024A0 (en) | 2000-02-15 | 2001-02-15 | Conjugates of a biopolymer and a therapeutic agent |
CA002400205A CA2400205A1 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
JP2001559507A JP2003522806A (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
EP01910775A EP1263472A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18255800P | 2000-02-15 | 2000-02-15 | |
US60/182,558 | 2000-02-15 | ||
US21150800P | 2000-06-14 | 2000-06-14 | |
US60/211,508 | 2000-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001060412A2 WO2001060412A2 (en) | 2001-08-23 |
WO2001060412A3 true WO2001060412A3 (en) | 2002-01-24 |
Family
ID=26878197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/004925 WO2001060412A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1263472A2 (en) |
JP (1) | JP2003522806A (en) |
AU (1) | AU2001238346A1 (en) |
CA (1) | CA2400205A1 (en) |
IL (1) | IL151024A0 (en) |
WO (1) | WO2001060412A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440684A (en) * | 2018-03-22 | 2018-08-24 | 华侨大学 | A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
JP2004525621A (en) * | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bifunctional fusion protein having glucocerebrosidase activity |
WO2004060404A1 (en) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
WO2005000884A1 (en) * | 2003-06-05 | 2005-01-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
EP1643958A4 (en) * | 2003-06-18 | 2010-09-01 | Nst Neurosurvival Technologies | Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
AU2004281694B2 (en) * | 2003-10-10 | 2012-05-03 | Cellular Bioengineering, Inc. | Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants |
US7625736B2 (en) | 2004-06-04 | 2009-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
WO2006028110A1 (en) | 2004-09-07 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
LT2457920T (en) | 2007-01-18 | 2018-02-12 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
CA2747230C (en) | 2008-12-16 | 2019-06-11 | Genzyme Corporation | Oligosaccharide-protein conjugates |
WO2012118189A1 (en) | 2011-03-03 | 2012-09-07 | 中外製薬株式会社 | Hyaluronic acid derivative modified by amino-carbonic acid |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
CN104603156B (en) | 2012-09-05 | 2016-10-26 | 中外制药株式会社 | Introduce and have aminoacid and the derivatives of hyaluronic acids of steroid base |
KR102049568B1 (en) * | 2013-04-01 | 2019-11-27 | 삼성전자주식회사 | Composition for nucleic acid delivery containing hyaluronic acid |
GB201602359D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
WO1993008842A1 (en) * | 1991-11-08 | 1993-05-13 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
WO1999066063A2 (en) * | 1998-06-16 | 1999-12-23 | Isis Pharmaceuticals, Inc. | Nucleosidic and non-nucleosidic folate conjugates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US5329029A (en) | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
EP0693924B2 (en) * | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US5354853A (en) | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
US5932552A (en) | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
-
2001
- 2001-02-15 WO PCT/US2001/004925 patent/WO2001060412A2/en active Application Filing
- 2001-02-15 CA CA002400205A patent/CA2400205A1/en not_active Abandoned
- 2001-02-15 AU AU2001238346A patent/AU2001238346A1/en not_active Abandoned
- 2001-02-15 EP EP01910775A patent/EP1263472A2/en not_active Ceased
- 2001-02-15 IL IL15102401A patent/IL151024A0/en unknown
- 2001-02-15 JP JP2001559507A patent/JP2003522806A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
WO1993008842A1 (en) * | 1991-11-08 | 1993-05-13 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
WO1999066063A2 (en) * | 1998-06-16 | 1999-12-23 | Isis Pharmaceuticals, Inc. | Nucleosidic and non-nucleosidic folate conjugates |
Non-Patent Citations (2)
Title |
---|
DADLEY-MOORE D L ET AL: "Synthetic peptide antigens induce antibodies to Taenia ovis oncospheres", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 11-12, March 1999 (1999-03-01), pages 1506 - 1515, XP004158279, ISSN: 0264-410X * |
GEORGE Y. WU AND CATHERINE H. WU: "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 10, 5 April 1987 (1987-04-05), pages 4429 - 4432, XP002176177 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440684A (en) * | 2018-03-22 | 2018-08-24 | 华侨大学 | A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
AU2001238346A1 (en) | 2001-08-27 |
EP1263472A2 (en) | 2002-12-11 |
IL151024A0 (en) | 2003-02-12 |
WO2001060412A2 (en) | 2001-08-23 |
CA2400205A1 (en) | 2001-08-23 |
JP2003522806A (en) | 2003-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
NO20015584L (en) | Long-lasting insulin-tropic peptides and conjugates and use in the manufacture of medicaments for treatment | |
ES2173641T3 (en) | COMPOSITION OF OPIACE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES. | |
WO2001085137A3 (en) | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | |
WO2006014673A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
ATE349438T1 (en) | CYTOTOXIC ACTIVE INGREDIENTS CONTAINING TAXANES AND THEIR THERAPEUTIC USE | |
WO2003061577A3 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
ATE432689T1 (en) | SUSTAINED RELEASE DRUG FORMULATIONS CONTAINING A CARRIER PEPTIDE | |
AU1079701A (en) | Oral transmucosal drug dosage using solid solution | |
DE60031793D1 (en) | DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE | |
WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
TR200200710T2 (en) | Pharmaceutical liquid compositions produced to prevent the unpleasant taste of the drug. | |
WO2003099225A3 (en) | Compositions for delivering nucleic acids to cells | |
TW200514590A (en) | Hydrophilic adhesives for delivery of herbal medicines | |
WO2002026191A3 (en) | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue | |
TW200635616A (en) | Organic compounds | |
WO2006138571A3 (en) | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance | |
WO1996040074A3 (en) | Device for releasing aggregation-stabilized, biologically active agent | |
DE60111637D1 (en) | BIOMATERIAL IN THE FORM OF MICROPARTICLES OF HYALURONIC SUCTION FOR MEDICAL USE | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
BE2016C017I2 (en) | ||
CN1190581A (en) | Complex rifampin injection | |
AU2001289762A1 (en) | Pharmaceutical extemporary compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151024 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2400205 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 559507 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001910775 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001910775 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 Ref country code: DE Ref legal event code: 8642 |